The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline
Open accessAbstract
Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. The role of imaging in prostate cancer should include diagnosis, localization, and characterization (indolent vs. lethal) of the primary tumor, determination of extracapsular spread, guidance and evaluation of local therapy in organ-confined disease, staging of locoregional lymph nodes, detection of locally recurrent and metastatic disease in biochemical relapse, planning of radiation treatment, prediction and assessment of tumor response to salvage and systemic therapy, monitoring of active surveillance and definition of a trigger for definitive therapy, and prognostication of time to hormone refractoriness in castrate disease and overall survival. To address these tasks effectively, imaging needs to be tailored to the specific phases of the disease in a patient-specific, risk-adjusted manner. In this article, I review the preclinical and clinical evidence on the potential and emerging role of PET with the 3 most commonly studied radiotracers in prostate cancer, namely 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
Liu, Y. (2006) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500879 · Cited by 433
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
SHREVE, P. D., Grossman, H. B., Gross, M. D., & Wahl, R. L. (1996) · Radiology · doi:10.1148/radiology.199.3.8638000 · Cited by 395
DeGrado, T. R., Coleman, R. E., Wang, S., BALDWIN, S. W., Orr, M. D., Robertson, C. N., Polascik, T. J., & Price, D. T. (2001) · PubMed · Cited by 368
Krause, B. J., Souvatzoglou, M., Tuncel, M., Herrmann, K., Buck, A. K., Praus, C., Schuster, T., Geinitz, H., Treiber, U., & Schwaiger, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0581-4 · Cited by 367
11C-acetate PET imaging in prostate cancer
Morris, M. J., & Scher, H. I. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0281-5 · Cited by 294
Beheshti, M., Imamovic, L., Broinger, G., Vali, R., Waldenberger, P., Stoiber, F., Nader, M., Gruy, B., Janetschek, G., & Langsteger, W. (2010) · Radiology · doi:10.1148/radiol.09090413 · Cited by 270
Liu, I. J., Zafar, M. B., Lai, Y.-H., Segall, G. M., & Terris, M. K. (2001) · Urology · doi:10.1016/s0090-4295(00)00896-7 · Cited by 267
Scattoni, V., Picchio, M., Suardi, N., Messa, C., Freschi, M., Roscigno, M., Da Pozzo, L., Bocciardi, A., Rigatti, P., & Fazio, F. (2007) · European Urology · doi:10.1016/j.eururo.2007.03.032 · Cited by 250
Cited by
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
Chen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., & Pomper, M. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1357 · Cited by 388
Ost, P., Bossi, A., Decaestecker, K., De Meerleer, G., Giannarini, G., Karnes, R. J., Roach, M., & Briganti, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.004 · Cited by 349
The metabolic fate of acetate in cancer
Schug, Z. T., Vande Voorde, J., & Gottlieb, E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.87 · Cited by 331
Evangelista, L., Zattoni, F., Guttilla, A., Saladini, G., Zattoni, F., Colletti, P. M., & Rubello, D. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182867f3c · Cited by 278
Metadata
- Authors
- Jadvar, H.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-12-13
- Volume
- 52
- Issue
- 1
- Pages
- 81-89
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2073380728
- Cited by
- 290
- References
- 41
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline. https://app.cochat.ai/papers/10.2967/jnumed.110.077941
- The paper
- Jadvar, H. (2011). Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.110.077941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.